net dbt
quick take ep beat higher sale
ex-u humira surpris guid rais modest
takeaway ep y/i con due
higher revenu better gross margin partial off-set higher oi vs con
est top-line came our/street notabl
beat includ humira ex-u vs vs con skyrizi
vs our/con partial off-set weaker hcv vs our/con
humira global sale came our/con forecast
respect us humira sale y/i came slightli mgmt
growth aspir mostli in-lin our/con estimate note us humira
growth lag script growth ppt second straight qtr recent
launch follow-on product skyrizi notabl out-perform suggest
may negoti payer portfolio-level drive skyrizi adopt
ex-u humira sale beat mgmt guid our/con
guidanc ep midpoint rais y/i growth
detail product level guidanc et conf call skyrizi charg
skyrizi sale well us/con expect question call regard
abbv chang fair valu skyrizi conting consider
relat futur mileston royalti payment presum result
lower ep outlook meaning
pipelin updat maintain neutral rate
area focu call
call focus skyrizi psoriasi launch updat management
bullish earli uptak skyrizi follow earli may us launch note
launch track significantli ahead expect note skyrizi
track close market lead launch although script data must
interpret grain salt market lead cosentyx/taltz
induct cours alway count singl script certain free good
program skyrizi cosentyx visibl script data call
management guid skyrizi sale assum result would
assum pbm formulari access juli
upadacitinib rheumatoid arthriti fda review given pdufa expect
fda adcom appear unlik consist mgmt prior
commentari management posit upa secur clean safeti label
box warn thromboembol advers event highlight low event rate
select view clean safeti label import upa reach mgmt
nomin sale ra indic eu humira specif whether
biosimilar eros stabil rel mgmt guidanc call
y/i oper basi report basi declin full year
basi expect ex-u humira eros oper basi us
approv senat financ committe advanc legisl full senat
abbv imbruvica venclexta focu oral cancer drug high price-tag
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net interest incom
fx impact report net sale
price object po base blend valuat risk-adjust
dcf pro forma entiti ev/ebitda multipl pro forma non-
gaap ep estim ev/ebitda multipl peer given modest
growth prospect assum wacc termin growth rate
pro forma entiti believ dcf assumpt reason minim
contribut pipelin valid late-stag clinic
downsid risk earlier-than-anticip launch humira biosimilar us
 integr risk clinic pipelin failur risk pend
transact
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
